Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial

BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced non-small cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. Cabozantinib, a small molecule tyrosine kinase inhibitor, targets MET, VEGFR, RET, ROS1, and AXL, which are implicated in lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Neal, Joel W., Dahlberg, Suzanne E., Wakelee, Heather A., Aisner, Seena C., Bowden, Michaela, Huang, Ying, Carbone, David P., Gerstner, Gregory J., Lerner, Rachel E., Rubin, Jerome L., Owonikoko, Taofeek K., Stella, Philip J., Steen, Preston D., Khalid, Ahmed Ali, Ramalingam, Suresh S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154681/
https://www.ncbi.nlm.nih.gov/pubmed/27825638
http://dx.doi.org/10.1016/S1470-2045(16)30561-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154681/
https://www.ncbi.nlm.nih.gov/pubmed/27825638
http://dx.doi.org/10.1016/S1470-2045(16)30561-7

Ejemplares similares